Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Last year marked a decade since the first checkpoint inhibitor, a monoclonal antibody (mAb) against CTLA4, was approved by the FDA to treat melanoma. This approval revolutionized cancer treatment and paved the way for clinical advances with immune checkpoint inhibitors and other immuno-oncology (IO) therapies. To date, the FDA has approved seven immune checkpoint inhibitors for the PD1/PDL1 pathway: four anti-PD1 and three anti-PDL1 mAbs, including the anti-PD1 mAb dostarlimab, approved in April 2021. This report provides an updated landscape of PD1/PDL1 clinical trials, including use of approved therapies in the clinic and a summary of emerging modalities.